Engineered Immunologic Niche Monitors Checkpoint Blockade Response and Probes Mechanisms of Resistance.
biomaterials
checkpoint blockade
immunotherapy resistance
metastasis
therapy monitoring
Journal
Immunomedicine
ISSN: 2510-5345
Titre abrégé: Immunomedicine
Pays: Germany
ID NLM: 9918249608506676
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
pmc-release:
01
06
2025
medline:
9
9
2024
pubmed:
9
9
2024
entrez:
9
9
2024
Statut:
ppublish
Résumé
Antibodies to programmed cell death protein1 (anti-PD-1) have become a promising immunotherapy for triple negative breast cancer (TNBC), blocking PD-L1 signaling from pro-tumor cells through T cell PD-1 receptor binding. Nevertheless, only 10-20% of PD-L1
Identifiants
pubmed: 39246390
doi: 10.1002/imed.1052
pmc: PMC11376346
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
Conflict of Interest Statement: L.D.S. and J.S.J. consult and have financial interests in COUR Pharmaceutical Development, Inc.